In today's Asking Eric column, R. Eric Thomas responds to someone who now has a fractured relationship with their sister ...

Collaboration between patients and doctors is crucial, says columnist Cazandra Campos-MacDonald, who stresses the value of meeting halfway.

Novo Nordisk said the overhaul resulted in one-off costs of about DKK 9 billion in 2025, including DKK 5 billion in severance ...

Investing.com -- Novo Nordisk (CSE:NOVOb) on Wednesday said it will cut about 9,000 jobs worldwide, including 5,000 in ...

Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

This mental health condition, sometimes called skin picking or excoriation disorder, involves picking the skin so much that ...

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...

Amid slow sales, BioMarin will continue to make the gene therapy commercially available in the US, Italy, and Germany while it finalizes next steps.

The company raised its full-year 2025 total revenue guidance to $3.15-3.2 billion from its previous outlook of $3.125-3.2 billion, while maintaining its VOXZOGO revenue forecast of $900-935 million.